SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PepGen
1. Faruqi & Faruqi is investigating potential claims against PepGen for misleading statements. 2. Investors have until August 11, 2025, to participate in a class-action lawsuit. 3. PepGen's trials faced challenges, leading to significant stock price declines. 4. The FDA expressed concerns about PepGen's clinical studies leading to halts. 5. PGN-EDO51 development was discontinued after failing to achieve target goals.